NOVOZYMES BIOINDUSTRIAL A/SActive
Key figures
Key ratios
2025Balance sheet structure
Corporate tax
The company is jointly taxed. Tax is assessed collectively at the administration company Novo Holdings A/S.
Source: the Danish Tax Agency's public company tax lists. Calculated tax for the income year; may be lower than 22% of income, e.g. when tax is paid abroad. sktst.dk
Financial statements2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||||
| Cash and cash equivalents | 279.025 | 615.139 | 581.735 | 515.028 | 495.563 | 0 | — | — | — |
| Total current assets | 417.359 | 691.549 | 590.621 | 532.124 | 513.201 | 207.945 | 178.298 | 147.257 | 102.513 |
| Total non-current assets | 26.934.066 | 25.775.503 | 25.775.503 | 31.056.827 | 31.756.827 | 28.831.397 | 24.837.414 | 24.837.414 | 24.837.414 |
| Total assets | 27.351.425 | 26.467.052 | 26.366.124 | 31.588.951 | 32.270.028 | 29.039.342 | 25.015.712 | 24.984.671 | 24.939.927 |
| Balance sheet — liabilities and equity | |||||||||
| Current liabilities | 31.250 | 69.422 | 0 | 31.250 | 2.795.546 | 35.373 | 38.775 | 49.434 | 48.870 |
| Non-current liabilities | 26.151.637 | 0 | — | 2.720.684 | 0 | — | — | — | — |
| Total liabilities | 26.182.887 | 69.422 | 0 | 2.751.934 | 2.795.546 | 35.373 | 38.775 | 49.434 | 48.870 |
| Share capital | 1.100.000 | 2.100.000 | 2.100.000 | 2.100.000 | 2.100.000 | 4.600.000 | 4.600.000 | 4.600.000 | 4.600.000 |
| Retained earnings of previous periods | 68.538 | -4.702.370 | -4.733.876 | -2.262.983 | -1.625.518 | -4.596.031 | 20.376.937 | 20.335.237 | 20.291.057 |
| Profit for the year | -5.390.460 | -4.770.908 | -31.506 | 2.470.893 | 637.465 | -2.970.513 | -4.027.032 | -41.700 | -44.180 |
| Total equity | 1.168.538 | 26.397.630 | 26.366.124 | 28.837.017 | 29.474.482 | 29.003.969 | 24.976.937 | 24.935.237 | 24.891.057 |
| Income statement | |||||||||
| Gross profit | — | — | — | — | -32.188 | -36.983 | -40.804 | -51.118 | -52.056 |
| Operating profit | -74.165 | -57.918 | -37.567 | -31.604 | -32.188 | -36.983 | -40.804 | -51.118 | -52.056 |
| Profit before income tax | -5.528.794 | -4.847.318 | -40.392 | 2.462.683 | 619.827 | -2.981.940 | -4.036.353 | -53.462 | -56.641 |
| Profit for the reporting year | -5.390.460 | -4.770.908 | -31.506 | 2.470.893 | 637.465 | -2.970.513 | -4.027.032 | -41.700 | -44.180 |
| Labour costs | — | — | — | — | — | — | — | — | — |
| Depreciation of non-current assets | — | — | — | — | — | — | — | — | — |
| Other indicators | |||||||||
| Employees | — | — | 0 | 0 | 0 | 0 | — | — | — |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
About the company
Annual report 2025The purpose of the company is to operate and invest in research and development, production and trade with biological solutions, including biotechnological products and processes, as well as any business related to this as determined by the Board of Directors. The purpose is in part fulfilled through the ownership of subsidiaries and associates. The company strives to operate in a sustainable and responsible way, both financially, socially and environmentally.
Excerpt from the management's review in the latest annual report.